Future Research Directions in Asthma - ATS Journals

NHLBI Workshop Future Research Directions in Asthma An NHLBI Working Group Report William Busse, Susan Banks-Schlegel, Patricia Noel, Hector Ortega, Virginia Taggart, and Jack Elias Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Division of Lung Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland; and Department of Internal Medicine, Yale University, New Haven, Connecticut

Over the last 20 years, the prevalence of asthma has nearly doubled and now affects 8–10% of the population in the United States. Asthma also remains a major illness in terms of morbidity and suffering, and is the leading cause of hospitalizations in children under 15 years of age. Because asthma poses a lifelong burden to patients and society, efforts to increase the understanding of its pathogenesis are a key factor leading to its control and cure. Consequently, the National Heart, Lung, and Blood Institute (NHLBI) convened a Working Group of extramural experts, entitled “Future Research Directions in Asthma,” on April 9–10, 2003, to identify research areas of greatest promise and opportunity in the field of asthma. The priority areas identified for research in asthma include: (1 ) innate immunity, adaptive immunity, and tolerance; (2 ) mechanisms and consequences of persistent asthma and asthma exacerbations; (3 ) airway remodeling: clinical consequences and reversibility (clinical relevance and resolution); (4 ) genetics/gene–environment interactions, pharmacogenetics; (5 ) intervention/prevention/therapeutics; and (6 ) vascular basis of asthma. Keywords: airway lung disease; asthma; innate immunity, asthma genetics; asthma exacerbations

In the world and in the United States, the prevalence of asthma continues to increase. Although there has been a plateau of the markers of asthma severity, i.e., hospitalization and deaths, the impact of this disease on individuals of all ages continues to be a major health risk. Furthermore, asthma begins early in life, and, for most patients, the consequences of this disease on airway function are apparent within a few years of onset and experienced for years to come. Therefore, despite the high prevalence of asthma and the recent advances from research applied to its understanding and control, asthma remains a major illness in terms of morbidity, suffering, and cost. Moreover, because remission of asthma is uncommon, this disease is likely to be one of a lifelong compromise. The Lung Division of the National Heart, Lung, and Blood Institute of the National Institutes of Health routinely convenes a group of investigators to review the direction for future research within asthma and to identify the opportunities for the scientific advancement, including basic, clinical, behavioral, and health education, and from this review develop short- and long-range strategic direction for supported investigation. On April 9 and 10, 2003, a group of investigators met to review the progress and direction of asthma research and from these discussions

provide the Institute with recommendations and priorities for new research opportunities in the broad aspects of asthma. Asthma, for most patients, begins in early life, and prenatal and immediate postnatal events have emerged as important in the early development and establishment of asthma. Central to these early-life processes are immune-related responses and their interaction with environmental factors such as allergens and infections, and the eventual development of either a normal immune response or an altered immune response, which may lead to the development of airway injury. Regulation of these inflammatory events is complex, interactive, and determined by gene–gene and gene–environmental interactions. Moreover, genetic processes are emerging as important in determining the response to therapy. It is also well appreciated that airway inflammation in asthma is complex and likely involves innate and adaptive responses, pathologic Th2 sensitization, and alterations in tolerance. It is also believed that this resulting inflammation and airway injury, in some manner, alters airway function and generates clinical symptomatology. Moreover, the appreciation that asthma is a disease characterized by chronic inflammation and repeated inflammatory exacerbations has led to the belief that these responses induce cycles of injury and repair that produce airway remodeling (1). Although it has not been convincingly proven, a variety of lines of evidence suggest that remodeling processes play an important role in disease pathogenesis, natural history, and physiologic dysregulation (Figure 1) (2). Given this background from advances in asthma, the availability of new techniques for study, and an emerging state of knowledge, the advisory group evaluated areas of potentially important research. The background, potential opportunities, and focus of new research areas were presented and discussed. The potential impact and importance of these research areas were considered by the advisory panel and then prioritized into subject areas that likely hold the most promise and opportunity to gain new insights into mechanisms of asthma, improved diagnosis, and more effective treatment. The research areas identified to have the greatest interest to the overall field of asthma are listed in order of priority (Table 1).

PRIORITY 1: INNATE IMMUNITY, ADAPTIVE IMMUNITY, AND TOLERANCE Background

(Received in original form November 12, 2003; accepted in final form June 16, 2004) Correspondence and requests for reprints should be addressed to Susan BanksSchlegel, Ph.D., DLD/NHLBI, Two Rockledge Center, Room 10018, 6701 Rockledge Drive, Bethesda, MD 20892-7952. E-mail: [email protected] Am J Respir Crit Care Med Vol 170. pp 683–690, 2004 Originally Published in Press as DOI: 10.1164/rccm.200311-1539WS on June 23, 2004 Internet address: www.atsjournals.org

The interplay between the immune system and the development of host-defense mechanisms is pivotal to the pathogenesis of respiratory illnesses and asthma. In the last five years, considerable progress has been achieved in understanding the complexities and division of the immune response into separate but interdependent compartments (3). The innate immune system is intrinsically present in the host and is the early or initial responder to various environmental insults, i.e., infections. In addition, toll-like recep-

684

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 170 2004

standing of the roles and mechanisms of tolerance in asthma is needed. These studies could include work to determine how tolerance and regulatory T cells may protect against the development of asthma and to determine how the developmental state of the immune system determines the response to tolerance stimuli. Based upon an expanded understanding of tolerance and protective immunity, and the development of the immune system, research toward the discovery of novel and curative therapies should be possible. 3. Innate immunity and adaptive immunity. Research into interventions and mutual influences of the innate and adaptive immune system should provide insight in the development of novel and potentially curative/preventive therapies. Figure 1. Airway inflammation and remodeling. A genetic predisposition may induce susceptibility of individuals with asthma to develop aberrant injury-repair responses. Such could induce physiologically relevant airway remodeling, manifested by irreversible airway obstruction (53).

tors have been identified, and their importance in the regulation of these responses is just beginning to be understood (3–6). The adaptive immune response, in contrast, is closely linked to pathogenic factors in asthma (7). Critical in these responses are subpopulations of lymphocytes, Th1, and Th2, and their role in adaptive response to allergens, for example, which result in IgE synthesis and have been a focus of ongoing research in asthma and important in understanding some mechanisms of allergic sensitivity. Tolerance is also an expanded component of the immune response and is a self-protective host response to prevent the development of allergy. Evidence now suggests that development of a specific T cell subpopulation, T regulatory cells, is important in this process. Early life events condition the immune response, and the initial response of the immune system is dictated and directed by the innate immune system. An understanding of the contribution and influence of the innate immune response to immunology, in general, has just begun to emerge and its role in the eventual development of asthma and its persistence has yet to be explored or established. There are a number of areas of research that appear to be of great potential to discover mechanisms of asthma and, as a consequence, hold considerable promise for new and novel investigation. As the innate immune system is likely a key event in the initiation of asthma, this is an area of considerable priority. Research Opportunities

1. Innate and adoptive immunity in asthma. Research should be directed toward understanding the mechanisms and contributions of innate immunity in asthma in areas such as toll-like receptors, defensins, and asthma susceptibility genes. The interactions between innate and adaptive immunity in relationship to the response to infections and allergen exposure early in life and once asthma has been established are likely important to mechanisms of asthma. Studies to define how the developmental state of the immune system determines the responses to innate stimuli are not yet explored in asthma. Finally, efforts that explain additional mechanisms of Th2-driven immunity in the development of asthma, both in animal and human models, are of interest. 2. Tolerance and protective immunity. It is possible that either the development, or failure, to establish tolerance is important in asthma and contributes both to the initiation and persistence of asthma. Research directed toward an under-

4. Define the relationships between the function of the innate immune system and tolerance to clinical features and natural history of asthma. This information will help investigators to determine if interventions that alter innate immunity or tolerance have a potential therapeutic role in the treatment of prevention of asthma.

PRIORITY 2: MECHANISMS AND CONSEQUENCES OF PERSISTENT ASTHMA AND ASTHMA EXACERBATIONS Background

In the majority of patients with asthma, the first symptoms of disease occur before six years of age. Furthermore, data also suggest that events occurring either during fetal or early life are important risk factors for asthma, among these events are the development of immune responses, cytokine dysregulation, and responses to microbes. Changes in airway function associated with asthma also appear to develop early in life and early in the course of asthma. Given the importance of early life events in

TABLE 1. SUGGESTED PRIORITIES FOR RESEARCH AND EXAMPLES OF AREAS OF INVESTIGATION 1. Innate immunity, adaptive immunity, and tolerance a. Innate and adoptive immunity in asthma b. Tolerance and protective immunity c. Relationships between functions of innate immunity and natural history of asthma 2. Mechanisms and consequences of persistent asthma and asthma exacerbations a. Mechanisms of chronicity/persistence b. Mechanisms determining severity c. Mechanisms and consequences of asthma exacerbations d. Define roles of risk factors including obesity 3. Mechanisms of airway inflammation, injury, and repair or remodeling a. Mechanisms of inflammation leading to remodeling b. Mechanisms of airway function and inflammation c. Airway cell-lung structure interaction 4. Genetics/gene–environment interactions, pharmacogenetics a. Identify all relevant susceptible variants in environment-specific and population contexts b. Characterize the function of susceptible genetic variants c. Incorporate genetics information into clinical management of asthma 5. Intervention/prevention/therapeutics a. Establish marker for features of asthma traits b. Develop strategies to prevent the progression of asthma c. Compare the importance of risk factors to inception and progression of asthma 6. Vascular basis of asthma a. Characterize effects of vascular mechanisms to features of asthma b. Establish relationship between vascular biology and inflammatory/ remodeling process in asthma

NHLBI Workshop

the origins of asthma, this “window of opportunity” appears to be a key to gain new insights into mechanisms of asthma and treatments directed toward prevention. Longitudinal studies have suggested that early events in the setting of genetic predisposition can result in the eventual presentation and eventual initiation of asthma in some individuals and possibly its persistence and severity. These early-life events may be related to many factors including nutrition during pregnancy, infection, or hormonal influences (8). Therefore, early identification of the high-risk individual may serve to alter the natural history of the disease by prompt therapy and/or environmental modification and to provide further insight into mechanisms of asthma (9). In addition, an enhanced understanding of the mechanisms that underlie these interventions may allow for specific interventions that can be applied later in life that will also alter the disease’s natural history and its severity. The mechanisms driving the gene-by-environment interaction that result in altered airway structure are poorly understood but are an important factor in asthma determination. Furthermore, the effects of basic cellular mechanisms on the physiology and exacerbations of asthma are important, but not fully defined. The consequences of asthma chronicity and its relationship both to persistence and disease severity are not well defined. Nonetheless, epidemiologic studies have shown that lung function may decline at a greater rate in some patients with asthma than in normal subjects (10, 11). The role of remodeling in this response and the degree to which the response is a consequence of persistence or severity has yet to be established. Furthermore, even potent antiinflammatory therapy, which controls symptoms, does not lead to disease modification as asthma symptoms and other physiologic abnormalities return with withdrawal of medication (12, 13). Thus, understanding the factors leading to chronicity, possibly severity, and loss of lung function appear central to future therapy and modification of asthma’s natural history. The mechanisms that underlie asthma severity are equally poorly defined. Many factors likely play a role in defining asthma severity. For example, the immune (innate, adaptive, or immune tolerance) and inflammatory responses in patients with severe asthma may be different than in patients with mild disease (14). Alternatively, they can differ in their remodeling responses or in ways that alter the sensitivity of their airway target tissues. Although there is considerable information on the immunopathology of asthma, the translation of these responses to asthma persistence and severity, and, most importantly, structural and functional changes has not been established. There is also little information on the role of central nervous system factors in determining asthma severity and the relationship of psychoneurologic processes either to the regulation of these features of asthma or disease severity (15). In addition, it is possible, but not proven, that patient behavior and compliance during treatment may influence these processes. As noted above, a large number of risk factors for asthma have been identified, e.g., genetics, infections, allergens, early use of antibiotics, and urban versus rural living. There is also mounting evidence that obesity is a risk factor in the development of asthma. In light of an increasing prevalence of obesity in our population, obesity may assume considerable significance and importance in the pathogenesis of asthma. Furthermore, it is not established whether obesity per se, or physical inactivity, is a predisposing factor to obesity or a comorbid problem. A number of other unexplained and unidentified factors likely contribute to the effect of obesity on asthma: endocrine (particularly hormones associated with growth and reproduction), diet (antioxidants, etc.), environment, physical activity and exercise, or

685

lack thereof. Furthermore, there is evidence that sex (female ⬎ male), ethnicity, and inner-city dwelling may also contribute to this process. Areas for study also include the influence of stress, the interaction of obesity with immunity, inflammation and injury/repair, and genetics. Furthermore, novel therapeutic interventions are needed to accomplish these goals; not only are human studies needed, but also the development of animal models. Asthma exacerbations are a major cause of deaths and largely determine health care costs, and often occur despite ongoing and appropriate therapy (16). The mechanisms of asthma exacerbations have not been well defined, nor have the relationships of asthma exacerbations to persistence, chronicity, and severity of disease. It is not established or understood why minority groups appear to have more frequent and severe exacerbations (17). Although considerable progress has been made through studies and lessons from cellular and animal models to human asthma, the correlation between structure and function should be emphasized. However, these same approaches have not been explored in studies to determine the causes, mechanisms, and translation of environmental and airway responses in asthma exacerbations. Although current therapy of asthma can prevent some exacerbations of asthma, these events still occur and are associated with increased risk for the patient and cost. As exacerbations area major source of morbidity in asthma, this area of research is of great interest and importance. Research Opportunities

1. Determine mechanisms in the chronicity/persistence of asthma and evaluate whether known or recently discovered infectious agents (e.g., viruses, microbes, etc.) are more likely to be found in individuals with persistent asthma; establish pathophysiological, genetic and molecular mechanisms to explain why the inflammatory response in asthma persists; evaluate different “step-down” treatment regimens that can be utilized in persistent asthma; and evaluate the optimal long-term regimen (including pharmacogenomics) for persistent asthma that provides satisfactory asthma control and lung function with minimal side effects. 2. Determine mechanisms that lead to asthma severity and evaluate whether the current NAEPP severity classification (18) leads to improved outcomes or whether alternative classification/treatment schemes (e.g., noninvasive measures of inflammation) should be used; assess if airway remodeling is related to asthma severity and lung function (crosssectional); and establish the characteristics of airway inflammation and the status/integrity of the airway epithelial cells in severe asthma and the relationships between these findings and the asthma phenotypes; evaluate whether certain genotypes identify individuals with a predisposition to severe disease; gain a better understanding of what makes severe asthma different from mild asthma (molecular, biologic, and genetic factors); assess if airway remodeling is related to asthma severity and lung function over time (longitudinal); evaluate whether the optimal treatment regimen for severe asthma should be guided by the characteristics of airway inflammation, genotype, and/or the phenotype. 3. Asthma exacerbations are major causes of asthma morbidity and mortality. Asthma exacerbations are most often caused by viral respiratory infections; the mechanisms by which these stimuli cause acute changes in the airway and result in pathophysiology of acute exacerbations have yet to be identified. In addition, the mechanisms by which these acute exacerbations resolve are not understood, or

686


whether they lead to further progress of the disease has yet to be explored.

PRIORITY 3: MECHANISMS OF AIRWAY INFLAMMATION/INJURY/REPAIR OR REMODELING Background

The recognition that airway inflammation is a central feature of asthma is important to an understanding of its persistence and chronicity (see above). Furthermore, the linkage of airway inflammation to the persistence and severity of clinical disease has, in turn, led to a greater employment of treatment whose principal action is the regulation of these processes. The discovery of subpopulations of lymphocytes (i.e., Th1/Th2), and other cell types, has also provided insight into the regulation of cellular events in inflammation. Precisely how these inflammatory events cause airway hyperresponsiveness, intermittent or persistent airflow obstruction, and exacerbations remains a puzzle, as well as the heterogeneity in different patients or the same patient under different conditions. Important in the initiation of allergic inflammation is an activation of many airway cells including subpopulations of T-helper lymphocytes, i.e., Th2. The role and contribution of Th1/Th2 lymphocytes and their products to allergic inflammation have been a major advance in understanding asthma and focus of current research efforts. At present, however, the mechanisms by which environmental factors, i.e., infections (viral and bacteria) or allergens, initiate, promote, and/or modulate airway inflammation, and the mechanisms by which these processes alter airway function, have yet to be fully established. Furthermore, the mechanisms by which Th2 cytokines mediate their tissue and physiologic effects, the importance of genetic control of Th2 cytokine effector function and cytokine regulation of resident effector cell populations (for example, epithelial cells, fibroblasts, airway smooth muscle, mucus gland cells, mast cells, and neural cells) versus inflammatory cells in the generation of asthmatic inflammation, remodeling, and physiologic dysregulation have not been fully defined. Cytokines and chemokines have contributed to the processes of inflammation, and they have a major effect on both migrating and resident lung cells from which they are also a source (19, 20). Finally, toll-like receptors have been identified as essential to innate immune responses (see discussion on innate immunity), but little is known about their role and contribution to the initiation and regulation of airway inflammation, injury/repair and bronchial dysfunction (Figure 1). This area of research remains a high priority as it is important to link immune function, or dysfunction, to altered airway physiology. Future Research Opportunities

1. A further understanding of the mechanisms by which inflammation and remodeling occur in the airway and lead to altered pulmonary function. Of special interest and attention are underinvestigated areas to define the processes that control the survival of populations of pathologic T lymphocytes and other inflammatory cells and quantitate their half-life in the normal and asthmatic lung. Such studies would help determine if therapeutic approaches that control inflammatory cell influx into the lung are likely to be useful in patients with established disease. 2. Studies of lung stem cell biology are also of interest and importance, and can lay the foundation for future investigations to determine if stem cell–based therapies might be useful in asthma.

3. Efforts to define the pathogenetic, physiologic, and clinical relevance of specific manifestations of airway remodeling to provide needed insights as to the roles of inflammation, injury, and repair in different cells and tissues in the airway in the genesis of physiologic dysregulation and the natural history, quality of life, and medication responsiveness of the disease. Such efforts will clarify the appropriateness of therapeutic interventions that are designed to control specific aspects of the remodeling response. 4. Research into the consequences of leukocyte–resident cell and resident cell–resident cell interactions (including dendritic cells) in regulating leukocyte/effector cell function are also of potential importance (21, 22). There is little information on the mechanisms regulating homing of T cells to the airway. There are few studies to examine differential gene expression in resident cells from normal subjects and subjects with asthma, and how these genes may differentially determine either the development of inflammation/injury/repair or their consequence on airway physiology. 5. Studies that will determine if ethnic, age, and/or sex variation in the cellular dysfunction, which can alter airway inflammation and or remodeling are of pathogenetic or clinical importance. 6. Research is also needed on new therapeutics that will specifically address the consequences of airway remodeling. To accomplish these goals, natural history studies to define the physiologic consequences of airway remodeling are needed as well as studies that explore the relative importance of age, sex, and ethnicity both into relationship of the cellular and genetic factors that promote and influence airway inflammation and obstruction.

PRIORITY 4: GENETICS/GENE–ENVIRONMENT INTERACTIONS, PHARMACOGENETICS Background

Asthma genetics has made significant progress in the past decade. Regions of the genome with detectable effects have been identified through genomic scans. In addition, the specific genes that are responsible for these effects, in many cases, have been identified, for example, ADAM33, IL4RA, IL13, and CD14 (23). Furthermore, new evidence has emerged to highlight the importance of environmental exposures in the development of asthma. For example, interactions with environmental tobacco smoke have been reported in linkage studies (24) and associations have been noted between polymorphisms in the CD14 and TLR4 genes and endotoxin expososure (25, 26). This information has become important to explain the lower prevalence of asthma in rural areas and possible risk for asthma with cigarette smoke exposure. Studies have also provided evidence of genotypes influencing the response of patients to various asthma medications in the treatment of their asthma. For example, bronchodilator response to ␤-agonists is associated with polymorphisms in the ␤2-adrenergic receptor gene (27–30). In addition, leukotriene synthesis genes may determine the effectiveness of drugs designed to regulate these processes (31). Along with the need to continue to identify all significant asthma susceptibility loci, future research needs in asthma genetics fall into two broad categories of investigation. First, there is the need to apply functional genomics approaches to better understand how specific genetic variants contribute to pathogenesis. This will need to be done in a context that allows for appropriate

NHLBI Workshop

investigations of variations in asthma susceptibility and response to drugs in environment-specific and population-specific contexts. Second, improved methodologic tools for studying gene–gene and gene–environment interaction in asthma (i.e., pharmacogenetics, ecogenetics, and epistasis) are required. This research is judged important, as it will provide tremendous opportunities to uncover the heterogeneity and complexities of the asthma syndrome. Research Opportunities

1. To identify all relevant susceptible variants in environmentspecific and population-specific contexts. This will need to incorporate studies of gene–environment interactions, including many of the known environmental risk factors such as endotoxin, viral infections, cigarette smoke, and allergens. Furthermore, genetic background in general and specific genes in particular can influence the expression of a particular gene. Although examples of gene-by-environment and gene-by-gene interactions have been demonstrated for asthma, it was suggested that a systematic study of these complex models of susceptibility is now warranted and appropriate. 2. To characterize the function of susceptible genetic variants. One of the potentially greatest challenges, and opportunities, in human genetics will be the identification of the biological effects of genetic variations and the mechanisms by which they associate with asthma variability. These variations are likely to have subtle effects on risk and may be evident only in specific contexts. Therefore, research focused on the interface between functional genomics and human genetic variation is critically important to understand the mechanisms of genetic risk for asthma. 3. To incorporate genetics information into the clinical management of asthma. The ultimate goal of genetic studies in asthma is to use this information to identify treatment options, to predict disease outcomes, and to identify atrisk individuals to initiate preventive strategies.

INITIATIVE 5: INTERVENTION/ PREVENTION/THERAPEUTICS Background

In the past four years, nearly 1,700 citations have considered the approaches of intervention and prevention in asthma. From these observations, asthma prevention has been considered at the primary, secondary, and tertiary levels. For example, environmental control of allergen exposure has been explored as a treatment of asthma, with variable results (32, 33). The basis for such differences in these various studies has not been defined but might hold clues as to mechanisms of disease and phenotypic variation. Early life events have also been found to be risk factors for asthma or as factors that may modify expression of the disease (34, 35). For example, cigarette smoke, even during the prenatal period, has been found to be a risk factor for asthma (36, 37). Conversely, a rural environment appears to be protective from the expression of asthma (38). Finally, recent evidence has begun to suggest that early exposure to animals, i.e., cats and/or dogs, can reduce the risk of asthma (39, 40). With the recognition that immune factors, even early in life, may contribute to the pathogenesis of asthma, research has begun to focus on understanding the links between innate and adaptive immunity (see above) in early life and how these responses can be modulated to allow for correction of cytokine and/or other types of immunologic dysregulation and their subsequent effects on the development of the asthmatic phenotype

687

(41, 42). Recently, standard immunotherapy with environmental allergens during childhood has been evaluated and shown to reduce the likelihood that asthma will develop in a high-risk population (children with allergic rhinitis only at the start of immunotherapy) (43). Other approaches that may modulate immune development, such as DNA vaccination, are also under active investigation (44). The treatment of asthma is a multiphased and multifaceted approach with variable outcomes. Although current therapeutics for asthma are effective and safe, successful and far-reaching control of asthma has been incomplete. To advance the translation of the understanding of asthma mechanisms to clinical intervention, a number of important areas of research were identified. These include the importance of adherence in asthma treatment, not only at the level of application but also understanding factors that determine this behavior and its importance to asthma phenotypes and genotypes. The mechanisms underlying behavior, and behavior modification to therapy of asthma and possibly underlying mechanisms, are needed. Research into how ethnicities, sex, and age, as well as other disparities of certain groups have effects on asthma and the response to asthma treatment (medications, perception, and environmental control, for example) is needed. Furthermore, the differences in response to treatment in different severities of asthma have yet to be explored. Therapeutics also needs to be studied in relationship to genetic factors, i.e., pharmacogenetics. Finally, therapeutics, which addresses asthma prevention, disease modification, and reversal of underlying mechanisms, are of particular need and importance. The effectiveness of intervention with antiinflammatory therapies, such as inhaled corticosteroids, has also been explored through cooperative studies such as Childhood Asthma Management Program (CAMP) and the Childhood Asthma Research and Education (CARE) Network, along with the Asthma Clinical Research Network (ACRN). These “networks” have not only been successful in evaluating the efficacy and effectiveness of asthma treatment, but they have provided new insights into characteristics of the disease and basic mechanisms as well. During discussions, it became clear to the advisory group that there were many agents/approaches that have already been developed for other purposes that could have a favorable impact on asthma, and that this area of study was also of considerable importance. Although available asthma management is generally effective, this area of research can be important to improve effectiveness (adherence and behavior modification), to seek out disease-modifying approaches, and to provide insight into basic mechanisms of disease and pharmacogenetics. Research Opportunities

1. To establish safe, informative, and standardized procedures for defining early inflammatory/remodeling markers in children who are at high risk of developing asthma during childhood. 2. To determine the relationship of observed inflammatory/ remodeling markers with immunologic profiles beginning in utero and their longitudinal effect prospectively in the first five years of life and physiologic, clinical phenotypes in the first decade of life, genotypes (asthma genes and pharmacogenetics), therapeutic (medications) responses, and behavioral factors. 3. To develop, evaluate, and compare strategies (nature of the intervention, time of initiation of the intervention, and duration of treatment to measurable response) that have the potential, either alone or in combination, to reduce or eliminate the “allergic march” in children. Examples

688


include environmental control, anti-IgE, and other immunebased interventions. 4. To compare and contrast epidemiologic, immunologic, physiologic, and genetic factors both in the inner cities and rural farming environments to determine their influence on asthma inception. 5. Pharmacogenetics to define drug treatment responses. These are currently radically new approaches to the field and practitioners, and studies will need to be adequately powered to make meaningful comparisons. 6. Preventive or curative therapies. It was proposed that special funding mechanisms might need to be established for these sorts of studies because these grants are rarely funded in regular study sections and are not often funded by industry. 7. Linkage of basic studies with clinical trials. Progress would be expedited if basic studies and human studies were linked in some fashion. This would allow for cross-fertilization between investigators. This could allow for the development of: a. Tissue banks, DNA banks, and proteomics banks from well-characterized patient populations; b. Ancillary studies as part of or distinct from the networks; c. The application of microarrays, and methodologies of genomics and proteomics to look for expression patterns that correlate with clinical manifestations and/or treatment response; and d. The development of standardized, NIH-accepted protocols that would facilitate the acquisition of human research samples and human investigation (for example, bronchoscopy, sputum induction, DNA and protein acquisition and storage).

INITIATIVE 6: VASCULAR BASIS OF ASTHMA Background

Acute antigen challenge of the airways can lead to rapid edema and appearance of plasma proteins in the airways. Furthermore, the airways of patients with asthma have elevated levels of macromolecules derived from blood compared with normal airways (45). Numerous pathways exist for the regulation of vascular tone, diameter, and leakage. More information is desirable to better understand the molecular processes by which vascular tissue and infiltrating cells alter the tone, permeability, and development of airway blood vessels. In addition, pathways for movement of macromolecules from extravascular sites into the airways are worthy of further study (46–48). The role of the vasculature in responses of the airways to exercise, hyperosmolarity, and cold air challenges is also an important area that is likely to improve our knowledge and treatment of asthma. Although there is increased vascularization in the lung associated with greater severity of asthma, little is understood about the angiogenic factors in asthma (49). In addition, although vascular endothelial growth factor (VEGF), for example, has been produced in an exaggerated fashion in asthma, the role that it and other growth factors play in asthma pathogenesis is poorly defined. Interestingly, this is one of the few components of airway remodeling that appears to be fully reversible with treatment with glucocorticoids. The role of growth factors, such as VEGF and angiopoietin, and other factors involved in regulating this process, and the importance of regulation by glucocorticoids and other drugs, are all areas worthy of further investigation. In

addition, the possibility that vascular regulators can have nonvascular effects in the lung has not been considered (50). Neuropeptides appear to have effects on angiogenesis in the lung, but there is little knowledge of how the nervous system may affect the vascularization process. There is increasing support for the idea that in asthma the efferent and afferent nerve fibers may be changed in their capacity to be stimulated. More work is necessary to delineate whether this could be one of the driving forces for increased vascularization. Endothelial cells express adhesion molecules in response to inflammatory cytokines, and these adhesion molecules are important in the recruitment of inflammatory cells (51, 52). There is evidence for cell type–selective adhesion molecules (e.g., VCAM-1), which can shape the nature of the inflammatory cell infiltrate. Endothelial cell–derived chemokines can be important in transendothelial migration. The presence of chemokines alone, however, is inadequate to induce inflammatory cell infiltration of the airways, suggesting that activation of endothelium is an essential component of the pathway for cell recruitment to the lungs. Blood vessels are very important in asthma. They are involved in the recruitment of inflammatory cells to the airway, contribute to the altered airway physiology, and secrete a variety of mediators that may determine or regulate the inflammatory response. Despite the recognized importance of vascular tissues to asthma pathophysiology, there are major gaps in our knowledge of this area. Identification of these gaps and the application of research to these areas is a priority. Research Opportunities

1. Characterization of the effects of vascular regulators such as the VEGF moieties, angiopoietins, etc., in the airway and their roles in asthma pathogenesis including mechanism(s) of tissue edema and angiogenesis in asthma, airway vascular remodeling, and tissue edema, and innate and adaptive immunity in asthma. 2. Characterization of the roles of vascular remodeling and tissue edema in the pathogenesis of the inflammatory, immune, structural, and physiologic abnormalities in asthma and their relationship to disease natural history. 3. Characterization of the effects of antiangiogenic interventions on the clinical and pathologic features and natural history of asthma and asthma models. 4. Characterization of the importance of and mechanisms of endothelial activation in asthma. Conflict of Interest Statement : W.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; S.B.-S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; P.N. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; H.O. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; V.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; J.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Acknowledgment : Participants: Co-Chairs—William Busse, M.D. (Madison, WI) and Jack Elias, M.D. (New Haven, CT); Group leaders—Group 1, Carole Ober, Ph.D. (Chicago, IL); Group 2, Reynold Panettieri, M.D. (Philadelphia, PA); Group 3, Robert Lemanske, M.D. (Madison, WI); Group 4, Dale Umetsu (Stanford, CA); Group 5, Mario Castro, M.D. (St. Louis, MO); Group 6, Scott Weiss, M.D. (Boston, MA); Group7, Cynthia Rand, Ph.D. (Baltimore, MD); Group 8, Robert Schleimer, Ph.D. (Baltimore, MD); Group 9, Monica Kraft (Denver, CO); Susan BanksSchlegel, Ph.D. (Bethesda, MD), James Kiley, Ph.D. (Bethesda, MD), Patricia Noel, Ph.D. (Bethesda, MD), Hector Ortega, M.D., Sc.D. (Bethesda, MD), Thomas PlattsMills, M.D., Ph.D. (Charlottesville, VA), Virginia Taggart, M.P.H. (Bethesda, MD), Yohannes Tesfaigzi, Ph.D. (Albuquerque, NM), Gail Weinmann, M.D. (Bethesda, MD), and Sandra Wilson, Ph.D. (Palo Alto, CA). The authors are very grateful to Kathryn Purcell for her excellent assistance in preparing this manuscript.

NHLBI Workshop References 1. Busse W, Elias J, Sheppard D, Banks-Schlegel S. Airway remodeling and repair. Am J Respir Crit Care Med 1999;160:1035–1042. 2. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, Bonsignore G. Airway remodeling in asthma. Chest 2003;123:417S– 422S. 3. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197–216. 4. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002;3:715–720. 5. Braun-Fahrlander C. Environmental exposure to endotoxin and other microbial products and the decreased risk of childhood atopy: evaluating developments since April 2002. Curr Opin Allergy Clin Immunol 2003;3:325–329. 6. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001;106:259–262. 7. Kumar SD, Emery MJ, Atkins ND, Danta I, Wanner A. Airway mucosal blood flow in bronchial asthma. Am J Respir Crit Care Med 1998;158: 153–156. 8. Guilbert T, Krawiec M. Natural history of asthma. Pediatr Clin North Am 2003;50:523–538. 9. Szefler SJ. Identifying the child in need of asthma therapy. Pediatr Clin North Am 2003;50:577–591. 10. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987;70:171–179. 11. Kelly WJ, Hudson I, Raven J, Phelan PD, Pain MC, Olinsky A. Childhood asthma and adult lung function. Am Rev Respir Dis 1988;138:26–30. 12. Brown PJ, Greville HW, Finucane KE. Asthma and irreversible airflow obstruction. Thorax 1984;39:131–136. 13. Castro M, Bloch S, Jenkerson M, DeMartino S, Hamilos R, Cochran R, Zhang XE, Wang H, Bradley JP, Schechtman KB. Asthma exacerbations after glucocorticoid withdrawal reflect T cell but not eosinophil recruitment to the airway. Am J Respir Crit Care Med 2004;169:842– 849. 14. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001–1008. 15. Busse WW, Kiecolt-Glaser JK, Coe C, Martin RJ, Weiss ST, Parker SR. NHLBI Workshop summary. Stress and asthma. Am J Respir Crit Care Med 1995;151:249–252. 16. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997;156:787–793. 17. Castro M, Schechtman KB, Halstead J, Bloomberg G. Risk factors for asthma morbidity and mortality in a large metropolitan city. J Asthma 2001;38:625–635. 18. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. 1997. National Institutes of Health; National Heart, Lung, and Blood Institute. 19. Panettieri RA Jr. Airway smooth muscle: an immunomodulatory cell. J Allergy Clin Immunol 2002;110:S269–S274. 20. Panettieri RA Jr. Airway smooth muscle: immunomodulatory cells that modulate airway remodeling? Respir Physiol Neurobiol 2003;137:277– 293. 21. Panettieri RA Jr. Airway smooth muscle: an immunomodulatory cell. J Allergy Clin Immunol 2002;110:S269–S274. 22. Panettieri RA Jr. Airway smooth muscle: immunomodulatory cells that modulate airway remodeling? Respir Physiol Neurobiol 2003;137:277– 293. 23. Hoffjan S, Ober C. Present status on the genetic studies of asthma. Curr Opin Immunol 2002;14:709–717. 24. Colilla S, Nicolae D, Pluzhnikov A, Blumenthal MN, Beaty TH, Bleecker ER, Lange EM, Rich SS, Meyers DA, Ober C. Evidence for geneenvironment interactions in a linkage study of asthma and smoking exposure. J Allergy Clin Immunol 2003;111:840–846. 25. Vercelli D, Baldini M, Stern D, Lohman IC, Halonen M, Martinez F. CD14: a bridge between innate immunity and adaptive IgE responses. J Endotoxin Res 2001;7:45–48.

689 26. Werner M, Topp R, Wimmer K, Richter K, Bischof W, Wjst M, Heinrich J. TLR4 gene variants modify endotoxin effects on asthma. J Allergy Clin Immunol 2003;112:323–330. 27. Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997;350: 995–999. 28. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997;100:3184–3188. 29. Kotani Y, Nishimura Y, Maeda H, Yokoyama M. Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J Asthma 1999;36:583–590. 30. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001;124:183–186. 31. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999;22:168–170. 32. Liu AH. Endotoxin exposure in allergy and asthma: reconciling a paradox. J Allergy Clin Immunol 2002;109:379–392. 33. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, Maisch S, Carr D, Gerlach F, Bufe A. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002;347:869–877. 34. Gern JE, Lemanske RF Jr, Busse WW. Early life origins of asthma. J Clin Invest 1999;104:837–843. 35. Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson Children’s Respiratory Study: 1980 to present. J Allergy Clin Immunol 2003;111:661–675. 36. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, Cowan JO, Herbison GP, Silva PA, Poulton R. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003;349:1414–1422. 37. Stein RT, Holberg CJ, Sherrill D, Wright AL, Morgan WJ, Taussig L, Martinez FD. Influence of parental smoking on respiratory symptoms during the first decade of life: the Tucson Children’s Respiratory Study. Am J Epidemiol 1999;149:1030–1037. 38. Braun-Fahrlander C. Environmental exposure to endotoxin and other microbial products and the decreased risk of childhood atopy: evaluating developments since April 2002. Curr Opin Allergy Clin Immunol 2003;3:325–329. 39. Ownby DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. JAMA 2002;288:963–972. 40. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 2001;357: 752–756. 41. McIntire JJ, Umetsu SE, Macaubas C, Hoyte EG, Cinnioglu C, CavalliSforza LL, Barsh GS, Hallmayer JF, Underhill PA, Risch NJ. Immunology: hepatitis A virus link to atopic disease. Nature 2003;425:576. 42. Umetsu DT, Akbari O, DeKruyff RH. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 2003;112:480–487. 43. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109: 251–256. 44. Broide D, Raz E. DNA-Based immunization for asthma. Int Arch Allergy Immunol 1999;118:453–456. 45. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253–257. 46. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003;3:253–257. 47. Wilson JW, Kotsimbos T. Airway vascular remodeling in asthma. Curr Allergy Asthma Rep 2003;3:153–158. 48. Boulay ME, Boulet LP. Airway response to low-dose allergen exposure

690


in allergic nonasthmatic and asthmatic subjects: eosinophils, fibronectin, and vascular endothelial growth factor. Chest 2003;123:430S. 49. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 2001;107:1034–1038. 50. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460–463.

51. Brieva J, Wanner A. Adrenergic airway vascular smooth muscle responsiveness in healthy and asthmatic subjects. J Appl Physiol 2001;90:665– 669. 52. Toppila S, Paavonen T, Laitinen A, Laitinen LA, Renkonen R. Endothelial sulfated sialyl Lewis x glycans, putative L-selectin ligands, are preferentially expressed in bronchial asthma but not in other chronic inflammatory lung diseases. Am J Respir Cell Mol Biol 2000;23:492– 498. 53. Lazaar AL, Panettieri R. Am J Med 2003;115:652–659.